The current state of the art and future trends in RAS-targeted cancer therapies

Nature Reviews Clinical Oncology, Published online: 26 August 2022; doi:10.1038/s41571-022-00671-9The RAS oncogenes are among the most common drivers of tumour development and progression but have historically been considered undruggable. The development of direct KRAS inhibitors has changed this paradigm, although currently clinical use of these novel therapeutics is limited to a select subset of patients, and intrinsic or acquired resistance presents an inevitable challenge to cure. Herein, the authors provide an overview of the RAS pathway in cancer and review the ongoing efforts to develop effective therapeutic strategies for RAS-mutant cancers. They also discuss the current understanding of mechanisms of resistance to direct KRAS inhibitors and strategies by which they might be overcome.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research